The GPHN Knockout HAP1 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the GPHN gene has been disrupted. This mixed population of HAP1 cells harbors diverse mutations at the target locus, creating a loss-of-function model suitable for studying gephyrin-dependent processes. As a polyclonal product, it avoids biases associated with single-cell clones and reflects the heterogeneity often desired in functional genomics experiments.
HAP1 is a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia (CML) line, with a predominantly haploid karyotype that simplifies genetic manipulation. Its origin from a male CML patient and robust growth characteristics make it a widely adopted system for CRISPR-based knockouts and high-throughput screening. The near-haploid state reduces the need for second-allele targeting, increasing the efficiency of loss-of-function generation.
Gephyrin acts as a central scaffold protein at inhibitory postsynaptic sites, directly binding the GlyR ?? subunit and GABA_A receptor ??2/??3 subunits to orchestrate receptor clustering. These interactions are mediated by collybistin and the adhesion molecule neuroligin-2, and are regulated by phosphorylation from kinases such as GSK-3??, ERK, CDK5, and CaMKII. Independently of its synaptic role, gephyrin functions as a bifunctional enzyme in the terminal steps of molybdenum cofactor (MoCo) biosynthesis, a pathway essential for molybdoenzymes like sulfite oxidase. Thus, gephyrin connects inhibitory neurotransmission to cellular metabolism.
Within the non-neuronal HAP1 context, the GPHN knockout disrupts gephyrin??s enzymatic contribution to MoCo synthesis and its interaction with cytoskeletal elements such as tubulin, enabling focused study of metabolic and signaling roles. This model is particularly valuable for dissecting how upstream kinases regulate gephyrin stability and function without the confounding variables of synaptic structures. It also provides a clean background for reconstitution experiments in which wild-type or mutant gephyrin can be reintroduced to assess functional domains.
Applications include functional validation of GPHN mutations found in hyperekplexia, epilepsy, and autism spectrum disorder, and screening for agents that restore inhibitory signaling or MoCo biosynthesis. Standard assays such as immunofluorescence for gephyrin clustering after heterologous expression of receptors, co-immunoprecipitation of receptor-gephyrin complexes, and quantitative analysis of molybdenum cofactor levels by HPLC are directly applicable. For further information, please contact Ascent Research.
